# Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)

> **NCT07535489** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanjing Immunophage Biotech Co., Ltd** · enrollment: 144 (estimated)

## Conditions studied

- Moderately to Severely Active Ulcerative Colitis (UC)

## Interventions

- **DRUG:** IPG11406
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07535489
- **Lead sponsor:** Nanjing Immunophage Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-07
- **Primary completion:** 2028-12-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07535489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07535489, "Efficacy and Safety of IPG11406 in Moderately to Severely Active Ulcerative Colitis (Phase 2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07535489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*